Larkin, SET; Johnston, HE; Jackson, TR; Jamieson, DG; Roumeliotis, TI; Mockridge, CI; Michael, A; ... Townsend, PA; + view all Larkin, SET; Johnston, HE; Jackson, TR; Jamieson, DG; Roumeliotis, TI; Mockridge, CI; Michael, A; Manousopoulou, A; Papachristou, EK; Brown, MD; Clarke, NW; Pandha, H; Aukim-Hastie, CL; Cragg, MS; Garbis, SD; Townsend, PA; - view fewer (2016) Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study. British Journal of Cancer , 115 (9) pp. 1078-1086. 10.1038/bjc.2016.291.

Preview

Text bjc2016291.pdf - Published Version Download (1MB) | Preview

Abstract

Background: Prostate cancer (PCa) is the most common male cancer in the United Kingdom and we aimed to identify clinically relevant biomarkers corresponding to stage progression of the disease. Methods: We used enhanced proteomic profiling of PCa progression using iTRAQ 3D LC mass spectrometry on high-quality serum samples to identify biomarkers of PCa. Results: We identified 41000 proteins. Following specific inclusion/exclusion criteria we targeted seven proteins of which two were validated by ELISA and six potentially interacted forming an ‘interactome’ with only a single protein linking each marker. This network also includes accepted cancer markers, such as TNF, STAT3, NF-kB and IL6. Conclusions: Our linked and interrelated biomarker network highlights the potential utility of six of our seven markers as a panel for diagnosing PCa and, critically, in determining the stage of the disease. Our validation analysis of the MS-identified proteins found that SAA alongside KLK3 may improve categorisation of PCa than by KLK3 alone, and that TSR1, although not significant in this model, might also be a clinically relevant biomarker.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item